Global Duchenne Muscular Dystrophy Market Insights and Forecast to 2028

Report ID: 1542528 | Published Date: Jan 2025 | No. of Page: 91 | Base Year: 2024 | Rating: 4.4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Duchenne Muscular Dystrophy Product Introduction
    1.2 Market by Type
        1.2.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Exondys 51
        1.2.3 Emflaza
        1.2.4 Translarna
    1.3 Market by Application
        1.3.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Home Care
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Duchenne Muscular Dystrophy Sales Estimates and Forecasts 2017-2028
    2.2 Global Duchenne Muscular Dystrophy Revenue Estimates and Forecasts 2017-2028
    2.3 Global Duchenne Muscular Dystrophy Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Duchenne Muscular Dystrophy Sales by Region
        2.4.1 Global Duchenne Muscular Dystrophy Sales by Region (2017-2022)
        2.4.2 Global Sales Duchenne Muscular Dystrophy by Region (2023-2028)
    2.5 Global Duchenne Muscular Dystrophy Revenue by Region
        2.5.1 Global Duchenne Muscular Dystrophy Revenue by Region (2017-2022)
        2.5.2 Global Duchenne Muscular Dystrophy Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Duchenne Muscular Dystrophy Sales by Manufacturers
        3.1.1 Global Top Duchenne Muscular Dystrophy Manufacturers by Sales (2017-2022)
        3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Duchenne Muscular Dystrophy in 2021
    3.2 Global Duchenne Muscular Dystrophy Revenue by Manufacturers
        3.2.1 Global Duchenne Muscular Dystrophy Revenue by Manufacturers (2017-2022)
        3.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Revenue in 2021
    3.3 Global Duchenne Muscular Dystrophy Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Duchenne Muscular Dystrophy Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Duchenne Muscular Dystrophy Sales by Type
        4.1.1 Global Duchenne Muscular Dystrophy Historical Sales by Type (2017-2022)
        4.1.2 Global Duchenne Muscular Dystrophy Forecasted Sales by Type (2023-2028)
        4.1.3 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2028)
    4.2 Global Duchenne Muscular Dystrophy Revenue by Type
        4.2.1 Global Duchenne Muscular Dystrophy Historical Revenue by Type (2017-2022)
        4.2.2 Global Duchenne Muscular Dystrophy Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2017-2028)
    4.3 Global Duchenne Muscular Dystrophy Price by Type
        4.3.1 Global Duchenne Muscular Dystrophy Price by Type (2017-2022)
        4.3.2 Global Duchenne Muscular Dystrophy Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Duchenne Muscular Dystrophy Sales by Application
        5.1.1 Global Duchenne Muscular Dystrophy Historical Sales by Application (2017-2022)
        5.1.2 Global Duchenne Muscular Dystrophy Forecasted Sales by Application (2023-2028)
        5.1.3 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2028)
    5.2 Global Duchenne Muscular Dystrophy Revenue by Application
        5.2.1 Global Duchenne Muscular Dystrophy Historical Revenue by Application (2017-2022)
        5.2.2 Global Duchenne Muscular Dystrophy Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2017-2028)
    5.3 Global Duchenne Muscular Dystrophy Price by Application
        5.3.1 Global Duchenne Muscular Dystrophy Price by Application (2017-2022)
        5.3.2 Global Duchenne Muscular Dystrophy Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Duchenne Muscular Dystrophy Market Size by Type
        6.1.1 North America Duchenne Muscular Dystrophy Sales by Type (2017-2028)
        6.1.2 North America Duchenne Muscular Dystrophy Revenue by Type (2017-2028)
    6.2 North America Duchenne Muscular Dystrophy Market Size by Application
        6.2.1 North America Duchenne Muscular Dystrophy Sales by Application (2017-2028)
        6.2.2 North America Duchenne Muscular Dystrophy Revenue by Application (2017-2028)
    6.3 North America Duchenne Muscular Dystrophy Market Size by Country
        6.3.1 North America Duchenne Muscular Dystrophy Sales by Country (2017-2028)
        6.3.2 North America Duchenne Muscular Dystrophy Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Duchenne Muscular Dystrophy Market Size by Type
        7.1.1 Europe Duchenne Muscular Dystrophy Sales by Type (2017-2028)
        7.1.2 Europe Duchenne Muscular Dystrophy Revenue by Type (2017-2028)
    7.2 Europe Duchenne Muscular Dystrophy Market Size by Application
        7.2.1 Europe Duchenne Muscular Dystrophy Sales by Application (2017-2028)
        7.2.2 Europe Duchenne Muscular Dystrophy Revenue by Application (2017-2028)
    7.3 Europe Duchenne Muscular Dystrophy Market Size by Country
        7.3.1 Europe Duchenne Muscular Dystrophy Sales by Country (2017-2028)
        7.3.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Duchenne Muscular Dystrophy Market Size by Type
        8.1.1 Asia Pacific Duchenne Muscular Dystrophy Sales by Type (2017-2028)
        8.1.2 Asia Pacific Duchenne Muscular Dystrophy Revenue by Type (2017-2028)
    8.2 Asia Pacific Duchenne Muscular Dystrophy Market Size by Application
        8.2.1 Asia Pacific Duchenne Muscular Dystrophy Sales by Application (2017-2028)
        8.2.2 Asia Pacific Duchenne Muscular Dystrophy Revenue by Application (2017-2028)
    8.3 Asia Pacific Duchenne Muscular Dystrophy Market Size by Region
        8.3.1 Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2017-2028)
        8.3.2 Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Duchenne Muscular Dystrophy Market Size by Type
        9.1.1 Latin America Duchenne Muscular Dystrophy Sales by Type (2017-2028)
        9.1.2 Latin America Duchenne Muscular Dystrophy Revenue by Type (2017-2028)
    9.2 Latin America Duchenne Muscular Dystrophy Market Size by Application
        9.2.1 Latin America Duchenne Muscular Dystrophy Sales by Application (2017-2028)
        9.2.2 Latin America Duchenne Muscular Dystrophy Revenue by Application (2017-2028)
    9.3 Latin America Duchenne Muscular Dystrophy Market Size by Country
        9.3.1 Latin America Duchenne Muscular Dystrophy Sales by Country (2017-2028)
        9.3.2 Latin America Duchenne Muscular Dystrophy Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Type
        10.1.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Type (2017-2028)
    10.2 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Application
        10.2.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Application (2017-2028)
    10.3 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Country
        10.3.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Sarepta Therapeutics
        11.1.1 Sarepta Therapeutics Corporation Information
        11.1.2 Sarepta Therapeutics Overview
        11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Sarepta Therapeutics Recent Developments
    11.2 PTC Therapeutics
        11.2.1 PTC Therapeutics Corporation Information
        11.2.2 PTC Therapeutics Overview
        11.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 PTC Therapeutics Recent Developments
    11.3 Pfizer
        11.3.1 Pfizer Corporation Information
        11.3.2 Pfizer Overview
        11.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Pfizer Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Pfizer Recent Developments
    11.4 Bristol-Myers Squibb
        11.4.1 Bristol-Myers Squibb Corporation Information
        11.4.2 Bristol-Myers Squibb Overview
        11.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Bristol-Myers Squibb Recent Developments
    11.5 Italfarmaco
        11.5.1 Italfarmaco Corporation Information
        11.5.2 Italfarmaco Overview
        11.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Italfarmaco Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Italfarmaco Recent Developments
    11.6 Santhera Pharmaceuticals
        11.6.1 Santhera Pharmaceuticals Corporation Information
        11.6.2 Santhera Pharmaceuticals Overview
        11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Santhera Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Duchenne Muscular Dystrophy Industry Chain Analysis
    12.2 Duchenne Muscular Dystrophy Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Duchenne Muscular Dystrophy Production Mode & Process
    12.4 Duchenne Muscular Dystrophy Sales and Marketing
        12.4.1 Duchenne Muscular Dystrophy Sales Channels
        12.4.2 Duchenne Muscular Dystrophy Distributors
    12.5 Duchenne Muscular Dystrophy Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Duchenne Muscular Dystrophy Industry Trends
    13.2 Duchenne Muscular Dystrophy Market Drivers
    13.3 Duchenne Muscular Dystrophy Market Challenges
    13.4 Duchenne Muscular Dystrophy Market Restraints
14 Key Findings in The Global Duchenne Muscular Dystrophy Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Exondys 51
    Table 3. Major Manufacturers of Emflaza
    Table 4. Major Manufacturers of Translarna
    Table 5. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Duchenne Muscular Dystrophy Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Duchenne Muscular Dystrophy Sales by Region (2017-2022) & (K Doses)
    Table 8. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2017-2022)
    Table 9. Global Duchenne Muscular Dystrophy Sales by Region (2023-2028) & (K Doses)
    Table 10. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2023-2028)
    Table 11. Global Duchenne Muscular Dystrophy Revenue by Region (2017-2022) & (US$ Million)
    Table 12. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2017-2022)
    Table 13. Global Duchenne Muscular Dystrophy Revenue by Region (2023-2028) & (US$ Million)
    Table 14. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2023-2028)
    Table 15. Global Duchenne Muscular Dystrophy Sales by Manufacturers (2017-2022) & (K Doses)
    Table 16. Global Duchenne Muscular Dystrophy Sales Share by Manufacturers (2017-2022)
    Table 17. Global Duchenne Muscular Dystrophy Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 18. Global Duchenne Muscular Dystrophy Revenue Share by Manufacturers (2017-2022)
    Table 19. Duchenne Muscular Dystrophy Price by Manufacturers (2017-2022) &(USD/Dose)
    Table 20. Global Duchenne Muscular Dystrophy Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 21. Global Duchenne Muscular Dystrophy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy as of 2021)
    Table 22. Duchenne Muscular Dystrophy Manufacturing Base Distribution and Headquarters
    Table 23. Manufacturers Duchenne Muscular Dystrophy Product Offered
    Table 24. Date of Manufacturers Enter into Duchenne Muscular Dystrophy Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
    Table 27. Global Duchenne Muscular Dystrophy Sales by Type (2023-2028) & (K Doses)
    Table 28. Global Duchenne Muscular Dystrophy Sales Share by Type (2017-2022)
    Table 29. Global Duchenne Muscular Dystrophy Sales Share by Type (2023-2028)
    Table 30. Global Duchenne Muscular Dystrophy Revenue by Type (2017-2022) & (US$ Million)
    Table 31. Global Duchenne Muscular Dystrophy Revenue by Type (2023-2028) & (US$ Million)
    Table 32. Global Duchenne Muscular Dystrophy Revenue Share by Type (2017-2022)
    Table 33. Global Duchenne Muscular Dystrophy Revenue Share by Type (2023-2028)
    Table 34. Duchenne Muscular Dystrophy Price by Type (2017-2022) & (USD/Dose)
    Table 35. Global Duchenne Muscular Dystrophy Price Forecast by Type (2023-2028) & (USD/Dose)
    Table 36. Global Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
    Table 37. Global Duchenne Muscular Dystrophy Sales by Application (2023-2028) & (K Doses)
    Table 38. Global Duchenne Muscular Dystrophy Sales Share by Application (2017-2022)
    Table 39. Global Duchenne Muscular Dystrophy Sales Share by Application (2023-2028)
    Table 40. Global Duchenne Muscular Dystrophy Revenue by Application (2017-2022) & (US$ Million)
    Table 41. Global Duchenne Muscular Dystrophy Revenue by Application (2023-2028) & (US$ Million)
    Table 42. Global Duchenne Muscular Dystrophy Revenue Share by Application (2017-2022)
    Table 43. Global Duchenne Muscular Dystrophy Revenue Share by Application (2023-2028)
    Table 44. Duchenne Muscular Dystrophy Price by Application (2017-2022) & (USD/Dose)
    Table 45. Global Duchenne Muscular Dystrophy Price Forecast by Application (2023-2028) & (USD/Dose)
    Table 46. North America Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
    Table 47. North America Duchenne Muscular Dystrophy Sales by Type (2023-2028) & (K Doses)
    Table 48. North America Duchenne Muscular Dystrophy Revenue by Type (2017-2022) & (US$ Million)
    Table 49. North America Duchenne Muscular Dystrophy Revenue by Type (2023-2028) & (US$ Million)
    Table 50. North America Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
    Table 51. North America Duchenne Muscular Dystrophy Sales by Application (2023-2028) & (K Doses)
    Table 52. North America Duchenne Muscular Dystrophy Revenue by Application (2017-2022) & (US$ Million)
    Table 53. North America Duchenne Muscular Dystrophy Revenue by Application (2023-2028) & (US$ Million)
    Table 54. North America Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
    Table 55. North America Duchenne Muscular Dystrophy Sales by Country (2023-2028) & (K Doses)
    Table 56. North America Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & (US$ Million)
    Table 57. North America Duchenne Muscular Dystrophy Revenue by Country (2023-2028) & (US$ Million)
    Table 58. Europe Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
    Table 59. Europe Duchenne Muscular Dystrophy Sales by Type (2023-2028) & (K Doses)
    Table 60. Europe Duchenne Muscular Dystrophy Revenue by Type (2017-2022) & (US$ Million)
    Table 61. Europe Duchenne Muscular Dystrophy Revenue by Type (2023-2028) & (US$ Million)
    Table 62. Europe Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
    Table 63. Europe Duchenne Muscular Dystrophy Sales by Application (2023-2028) & (K Doses)
    Table 64. Europe Duchenne Muscular Dystrophy Revenue by Application (2017-2022) & (US$ Million)
    Table 65. Europe Duchenne Muscular Dystrophy Revenue by Application (2023-2028) & (US$ Million)
    Table 66. Europe Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
    Table 67. Europe Duchenne Muscular Dystrophy Sales by Country (2023-2028) & (K Doses)
    Table 68. Europe Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & (US$ Million)
    Table 69. Europe Duchenne Muscular Dystrophy Revenue by Country (2023-2028) & (US$ Million)
    Table 70. Asia Pacific Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
    Table 71. Asia Pacific Duchenne Muscular Dystrophy Sales by Type (2023-2028) & (K Doses)
    Table 72. Asia Pacific Duchenne Muscular Dystrophy Revenue by Type (2017-2022) & (US$ Million)
    Table 73. Asia Pacific Duchenne Muscular Dystrophy Revenue by Type (2023-2028) & (US$ Million)
    Table 74. Asia Pacific Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
    Table 75. Asia Pacific Duchenne Muscular Dystrophy Sales by Application (2023-2028) & (K Doses)
    Table 76. Asia Pacific Duchenne Muscular Dystrophy Revenue by Application (2017-2022) & (US$ Million)
    Table 77. Asia Pacific Duchenne Muscular Dystrophy Revenue by Application (2023-2028) & (US$ Million)
    Table 78. Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2017-2022) & (K Doses)
    Table 79. Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2023-2028) & (K Doses)
    Table 80. Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2017-2022) & (US$ Million)
    Table 81. Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2023-2028) & (US$ Million)
    Table 82. Latin America Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
    Table 83. Latin America Duchenne Muscular Dystrophy Sales by Type (2023-2028) & (K Doses)
    Table 84. Latin America Duchenne Muscular Dystrophy Revenue by Type (2017-2022) & (US$ Million)
    Table 85. Latin America Duchenne Muscular Dystrophy Revenue by Type (2023-2028) & (US$ Million)
    Table 86. Latin America Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
    Table 87. Latin America Duchenne Muscular Dystrophy Sales by Application (2023-2028) & (K Doses)
    Table 88. Latin America Duchenne Muscular Dystrophy Revenue by Application (2017-2022) & (US$ Million)
    Table 89. Latin America Duchenne Muscular Dystrophy Revenue by Application (2023-2028) & (US$ Million)
    Table 90. Latin America Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
    Table 91. Latin America Duchenne Muscular Dystrophy Sales by Country (2023-2028) & (K Doses)
    Table 92. Latin America Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & (US$ Million)
    Table 93. Latin America Duchenne Muscular Dystrophy Revenue by Country (2023-2028) & (US$ Million)
    Table 94. Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
    Table 95. Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2023-2028) & (K Doses)
    Table 96. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Type (2017-2022) & (US$ Million)
    Table 97. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Type (2023-2028) & (US$ Million)
    Table 98. Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
    Table 99. Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2023-2028) & (K Doses)
    Table 100. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Application (2017-2022) & (US$ Million)
    Table 101. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Application (2023-2028) & (US$ Million)
    Table 102. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
    Table 103. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2023-2028) & (K Doses)
    Table 104. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & (US$ Million)
    Table 105. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2023-2028) & (US$ Million)
    Table 106. Sarepta Therapeutics Corporation Information
    Table 107. Sarepta Therapeutics Description and Major Businesses
    Table 108. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 109. Sarepta Therapeutics Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
    Table 110. Sarepta Therapeutics Recent Developments
    Table 111. PTC Therapeutics Corporation Information
    Table 112. PTC Therapeutics Description and Major Businesses
    Table 113. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 114. PTC Therapeutics Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
    Table 115. PTC Therapeutics Recent Developments
    Table 116. Pfizer Corporation Information
    Table 117. Pfizer Description and Major Businesses
    Table 118. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 119. Pfizer Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
    Table 120. Pfizer Recent Developments
    Table 121. Bristol-Myers Squibb Corporation Information
    Table 122. Bristol-Myers Squibb Description and Major Businesses
    Table 123. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 124. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
    Table 125. Bristol-Myers Squibb Recent Developments
    Table 126. Italfarmaco Corporation Information
    Table 127. Italfarmaco Description and Major Businesses
    Table 128. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 129. Italfarmaco Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
    Table 130. Italfarmaco Recent Developments
    Table 131. Santhera Pharmaceuticals Corporation Information
    Table 132. Santhera Pharmaceuticals Description and Major Businesses
    Table 133. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 134. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Model Numbers, Pictures, Descriptions and Specifications
    Table 135. Santhera Pharmaceuticals Recent Developments
    Table 136. Key Raw Materials Lists
    Table 137. Raw Materials Key Suppliers Lists
    Table 138. Duchenne Muscular Dystrophy Distributors List
    Table 139. Duchenne Muscular Dystrophy Customers List
    Table 140. Duchenne Muscular Dystrophy Market Trends
    Table 141. Duchenne Muscular Dystrophy Market Drivers
    Table 142. Duchenne Muscular Dystrophy Market Challenges
    Table 143. Duchenne Muscular Dystrophy Market Restraints
    Table 144. Research Programs/Design for This Report
    Table 145. Key Data Information from Secondary Sources
    Table 146. Key Data Information from Primary Sources
List of Figures
    Figure 1. Duchenne Muscular Dystrophy Product Picture
    Figure 3. Global Duchenne Muscular Dystrophy Market Share by Type in 2021 & 2028
    Figure 3. Exondys 51 Product Picture
    Figure 4. Emflaza Product Picture
    Figure 5. Translarna Product Picture
    Figure 6. Global Duchenne Muscular Dystrophy Market Share by Application in 2021 & 2028
    Figure 7. Hospitals
    Figure 8. Clinics
    Figure 9. Home Care
    Figure 10. Duchenne Muscular Dystrophy Report Years Considered
    Figure 11. Global Duchenne Muscular Dystrophy Sales 2017-2028 (K Doses)
    Figure 12. Global Duchenne Muscular Dystrophy Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Duchenne Muscular Dystrophy Revenue 2017-2028 (US$ Million)
    Figure 14. Global Duchenne Muscular Dystrophy Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 15. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2017-2022)
    Figure 16. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2023-2028)
    Figure 17. North America Duchenne Muscular Dystrophy Sales YoY (2017-2028) & (K Doses)
    Figure 18. North America Duchenne Muscular Dystrophy Revenue YoY (2017-2028) & (US$ Million)
    Figure 19. Europe Duchenne Muscular Dystrophy Sales YoY (2017-2028) & (K Doses)
    Figure 20. Europe Duchenne Muscular Dystrophy Revenue YoY (2017-2028) & (US$ Million)
    Figure 21. Asia-Pacific Duchenne Muscular Dystrophy Sales YoY (2017-2028) & (K Doses)
    Figure 22. Asia-Pacific Duchenne Muscular Dystrophy Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Latin America Duchenne Muscular Dystrophy Sales YoY (2017-2028) & (K Doses)
    Figure 24. Latin America Duchenne Muscular Dystrophy Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. Middle East & Africa Duchenne Muscular Dystrophy Sales YoY (2017-2028) & (K Doses)
    Figure 26. Middle East & Africa Duchenne Muscular Dystrophy Revenue YoY (2017-2028) & (US$ Million)
    Figure 27. The Duchenne Muscular Dystrophy Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 28. The Top 5 and 10 Largest Manufacturers of Duchenne Muscular Dystrophy in the World: Market Share by Duchenne Muscular Dystrophy Revenue in 2021
    Figure 29. Global Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 30. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2028)
    Figure 31. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2017-2028)
    Figure 32. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2028)
    Figure 33. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2017-2028)
    Figure 34. North America Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2028)
    Figure 35. North America Duchenne Muscular Dystrophy Revenue Market Share by Type (2017-2028)
    Figure 36. North America Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2028)
    Figure 37. North America Duchenne Muscular Dystrophy Revenue Market Share by Application (2017-2028)
    Figure 38. North America Duchenne Muscular Dystrophy Sales Share by Country (2017-2028)
    Figure 39. North America Duchenne Muscular Dystrophy Revenue Share by Country (2017-2028)
    Figure 40. U.S. Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 41. Canada Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 42. Europe Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2028)
    Figure 43. Europe Duchenne Muscular Dystrophy Revenue Market Share by Type (2017-2028)
    Figure 44. Europe Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2028)
    Figure 45. Europe Duchenne Muscular Dystrophy Revenue Market Share by Application (2017-2028)
    Figure 46. Europe Duchenne Muscular Dystrophy Sales Share by Country (2017-2028)
    Figure 47. Europe Duchenne Muscular Dystrophy Revenue Share by Country (2017-2028)
    Figure 48. Germany Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 49. France Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 50. U.K. Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 51. Italy Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 52. Russia Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 53. Asia Pacific Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2028)
    Figure 54. Asia Pacific Duchenne Muscular Dystrophy Revenue Market Share by Type (2017-2028)
    Figure 55. Asia Pacific Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2028)
    Figure 56. Asia Pacific Duchenne Muscular Dystrophy Revenue Market Share by Application (2017-2028)
    Figure 57. Asia Pacific Duchenne Muscular Dystrophy Sales Share by Region (2017-2028)
    Figure 58. Asia Pacific Duchenne Muscular Dystrophy Revenue Share by Region (2017-2028)
    Figure 59. China Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 60. Japan Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 61. South Korea Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 62. India Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 63. Australia Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 64. Taiwan Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 65. Indonesia Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 66. Thailand Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 67. Malaysia Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 68. Philippines Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 69. Latin America Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2028)
    Figure 70. Latin America Duchenne Muscular Dystrophy Revenue Market Share by Type (2017-2028)
    Figure 71. Latin America Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2028)
    Figure 72. Latin America Duchenne Muscular Dystrophy Revenue Market Share by Application (2017-2028)
    Figure 73. Latin America Duchenne Muscular Dystrophy Sales Share by Country (2017-2028)
    Figure 74. Latin America Duchenne Muscular Dystrophy Revenue Share by Country (2017-2028)
    Figure 75. Mexico Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 76. Brazil Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 77. Argentina Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 78. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2028)
    Figure 79. Middle East and Africa Duchenne Muscular Dystrophy Revenue Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Duchenne Muscular Dystrophy Revenue Market Share by Application (2017-2028)
    Figure 82. Middle East and Africa Duchenne Muscular Dystrophy Sales Share by Country (2017-2028)
    Figure 83. Middle East and Africa Duchenne Muscular Dystrophy Revenue Share by Country (2017-2028)
    Figure 84. Turkey Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 85. Saudi Arabia Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 86. U.A.E Duchenne Muscular Dystrophy Revenue (2017-2028) & (US$ Million)
    Figure 87. Duchenne Muscular Dystrophy Value Chain
    Figure 88. Duchenne Muscular Dystrophy Production Process
    Figure 89. Channels of Distribution
    Figure 90. Distributors Profiles
    Figure 91. Bottom-up and Top-down Approaches for This Report
    Figure 92. Data Triangulation
    Figure 93. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Frequently Asked Questions
Duchenne Muscular Dystrophy report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Duchenne Muscular Dystrophy report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Duchenne Muscular Dystrophy report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Ear Tube Devices

Ear Tube Devices market is segmented by Type and by Application. Players, stakeholders, and other ... Read More

Functional Film

Functional Film market is segmented by Type and by Application. Players, stakeholders, and other  ... Read More